Stockreport

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report
PDF - Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant seco [Read more]